Latest Market Entry News

Greenvale Energy has successfully scaled its Alpha Torbanite Project test program by 40 times and commenced bulk sample production aiming for commercial bitumen certification.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Prairie Lithium has locked in a decade-long agreement to supply lithium-bearing crystallite to Hydro Lithium’s South Korean refinery, marking a strategic step in its commercial-scale production and market entry.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

Merino & Co. has secured a significant new order from its Shanghai distribution partner, reinforcing its expanding footprint in China’s luxury apparel market and validating its strategic growth plans.

Imugene Limited has received positive feedback from the FDA, aligning key requirements to progress its azer-cel therapy into a pivotal clinical trial, underscoring its growing promise in blood cancer treatment.

Ovanti Limited’s US subsidiary has secured a key partnership with Mastercard’s Finicity to enhance its upcoming Flote BNPL platform, aiming to revolutionize consumer finance with real-time data insights.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

Lotus Resources reports promising progress at its Kayelekera uranium mine, targeting steady state production by Q1 2026 despite recent sulphuric acid supply constraints. The company is addressing supply issues with new sourcing and an on-schedule acid plant rebuild.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Proteomics International Laboratories has clarified that no undisclosed information explains its recent share price jump, pointing instead to recent Medicare reimbursement decisions and key product developments.